Learn More Learn More Collaboration with Mayo Clinic Adaptive Phage Therapeutics enters agreement with Mayo Clinic to commercialize a phage susceptibility test Learn More Learn More Precision Superbug Therapy Adaptive Phage Therapeutics, Inc. (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. Learn More Learn More Success Story In 2016 APT's approach achieved its first in-human success with the rescue of a critically ill MDR infected patient: Tom Patterson, multi-drug resistant Acinetobacter baumannii survivor Learn More Phage are the most prolific bacterial killers on Earth Watch the Video Learn More PhageBank

PhageBank is a large and dynamically growing collection of phage that attack specific targeted bacteria

Learn More

Antimicrobial Resistance (AMR) is a world-wide crisis caused by ongoing evolution of bacteria

APT PhageBank uniquely adapts in spectrum of coverage to overcome emerging bacterial resistance. Our approach addresses today’s – and tomorrow’s – toughest infections.

The Diminishing Effectiveness
of Antibiotics

The useful lifespan of new antibiotics has suffered due to the emergence of bacterial resistance. This cycle of introducing a new drug only to have bacteria evolve resistance is the pattern that APT’s ever-expanding PhageBank™ is designed to break.


This graphic shows the introduction of new classes of antibiotics, and the emergence of resistance to those drugs:

Thinking beyond the cycle of resistance:

Precise superbug therapy

Adaptive Phage Therapeutics (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria.

APT’s approach arms us with the unique capability of adapting to the emergence of future antibiotic-resistant superbugs. Our PhageBank’s precision targeted, genomically screened, and highly purified phage collection is dynamically expanding in response to the emergence of new strains of bacterial superbugs.

APT recognized as a leader in biotech

“Company To Watch”
2020, Life Science Leader

“Top 1% of Startups in the World” 
2020, Startup Grind Global Conference

“The Emerging Life Science Company of the Year” 
2020, Maryland Technology Council

“One of five biotech companies to watch in 2020”
2020, BiotechNews

“Emerging Business of the Year Finalist”
2019, Montgomery County Chamber 

“A High-momentum Game-Changing Startup of 2019”
2019, CB Insights

Success Story

In 2016 APT’s approach achieved its first in-human success with the rescue of a critically ill MDR infected patient: Tom Patterson, multi-drug resistant Acinetobacter baumannii survivor.

APT in the news

  • Adaptive Phage Therapeutics Receives Orphan Drug Designation
    Adaptive Phage Therapeutics (APT), announced the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for the treatment of prosthetic joint infections (PJI) utilizing PhageBank™.  Orphan drug designation is given […]
  • APT named 2020 Emerging Life Science Company of the Year
    The Maryland Tech Council (MTC), Maryland’s largest technology and life sciences trade association, announced the winners of its 32nd Annual Industry Awards. Due to COVID-19, the association pivoted to a virtual live broadcast to […]
  • APT Receives DoD Award for Development of COVID-19 Vaccine
    GAITHERSBURG, Md., August 19, 2020 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced the Department of Defense (DoD) awarded APT […]